By Colin Kellaher 



  Eli Lilly & Co. and Boehringer Ingelheim on Tuesday said they plan to study whether their diabetes drug Jardiance can improve outcomes and prevent heart failure in adults with and without diabetes who have had a heart attack. 


  The two companies said they will provide funding for the study, which they will conduct in partnership with the Duke Clinical Research Institute, part of Duke University's School of Medicine. 


  Eli Lilly and Boehringer Ingelheim said the study will include about 3,300 adults across at least 16 countries who have had an acute myocardial infarction, more commonly known as a heart attack. 


  Indianapolis-based drug maker Eli Lilly and Boehringer Ingelheim, a family-owned pharmaceutical company based in Ingelheim, Germany, jointly market Jardiance as part of a 2011 alliance. 


  The new study is part of a broader clinical program exploring the impact of Jardiance on patients across the spectrum of cardio-renal-metabolic conditions, the companies said. 


  Write to Colin Kellaher at colin.kellaher@wsj.com